tradingkey.logo
tradingkey.logo
検索

Immunoprecise Antibodies Ltd

IPA
ウォッチリストに追加
2.070USD
0.0000.00%
終値 07/02, 13:00ET15分遅れの株価
95.54M時価総額
損失額直近12ヶ月PER

詳細情報 Immunoprecise Antibodies Ltd 企業名

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.

Immunoprecise Antibodies Ltdの企業情報

企業コードIPA
会社名Immunoprecise Antibodies Ltd
上場日Jan 30, 1987
最高経営責任者「CEO」Dr. Jennifer Lynne Bath, Ph.D.
従業員数- -
証券種類Ordinary Share
決算期末Jan 30
本社所在地Industrious 823 Congress Ave Suite 300
都市AUSTIN
証券取引所NASDAQ Capital Market Consolidated
United States of America
郵便番号78701
電話番号16048060626
ウェブサイトhttps://www.ipatherapeutics.com/
企業コードIPA
上場日Jan 30, 1987
最高経営責任者「CEO」Dr. Jennifer Lynne Bath, Ph.D.

Immunoprecise Antibodies Ltdの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jennifer Lynne Bath, Ph.D.
Dr. Jennifer Lynne Bath, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
498.12K
--
Dr. Kamil Isaev
Dr. Kamil Isaev
Independent Director
Independent Director
3.19K
--
Mr. Dirk Witters
Mr. Dirk Witters
Independent Director
Independent Director
1.95K
--
Ms. Kari Graber
Ms. Kari Graber
Vice President - Commercial Services
Vice President - Commercial Services
700.00
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Director
Director
--
--
Mr. Joseph Scheffler
Mr. Joseph Scheffler
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Shuji Sato
Dr. Shuji Sato
Vice President - Innovative Solutions
Vice President - Innovative Solutions
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jennifer Lynne Bath, Ph.D.
Dr. Jennifer Lynne Bath, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
498.12K
--
Dr. Kamil Isaev
Dr. Kamil Isaev
Independent Director
Independent Director
3.19K
--
Mr. Dirk Witters
Mr. Dirk Witters
Independent Director
Independent Director
1.95K
--
Ms. Kari Graber
Ms. Kari Graber
Vice President - Commercial Services
Vice President - Commercial Services
700.00
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Director
Director
--
--
Mr. Joseph Scheffler
Mr. Joseph Scheffler
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--

よくある質問

Immunoprecise Antibodies Ltdの上位5名の株主は誰ですか?

Immunoprecise Antibodies Ltdの上位5名の株主は以下のとおりです。Dr. Jennifer Lynne Bath, Ph.D.

Immunoprecise Antibodies Ltd(IPA)の株式を保有している機関の数はいくつですか?

2026Q1時点で、Immunoprecise Antibodies Ltdの株式を保有している機関は47社あり、保有株式の総市場価値は約4.54Mで、全体の9.73%を占めています。2025Q4と比較して、機関の持ち株は212280.00増加しています。

Immunoprecise Antibodies Ltdの最大の収益源は何ですか?

2026Q1において、Project revenue部門がImmunoprecise Antibodies Ltdにとって最大の収益を生み出しており、その金額は4.11Mで、全収益の98.85%を占めています。